Donor Simvastatin Treatment in Organ Transplantation (NCT01160978) | Clinical Trial Compass
CompletedPhase 2/3
Donor Simvastatin Treatment in Organ Transplantation
Finland84 participantsStarted 2010-06-01
Plain-language summary
The aim of the study is to investigate the effects of donor simvastatin treatment on ischemia-reperfusion injury after heart transplantation.
Who can participate
Age range18 Years – 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria for a donor:
* Heart transplant donor
* Age 18-60 years
* Previously healthy
* No cholesterol medication
* Normal ECHO with LVEF \>45%, normal right ventricle and normal coronary angiography
* PiO2/FiO2 \> 40kPA, normal chest radiograph and normal bronchoscopy in lung donors
Exclusion Criteria for the heart/lung donor:
* Severe left ventricular hypertrophy \> 14 mm
* High dose of inotropes (dopamine or dobutamine \> 20ug/kg/min or norepinephrine \>0.2 ug/kg/min) at the time of procurement
* Donor outside of the study country Finland
Inclusion criteria for a transplant recipient:
* Age between 18-70 for heart transplant recipients
* Male or female
* Listed for heart, lung, kidney, or liver transplantation
Exclusive Criteria for the recipient
* systemic sepsis
* a positive cross match
What they're measuring
1
Donor treatment with simvastatin reduces ischemia-reperfusion injury after heart transplantation